Clinical decision thresholds for urine‐based fibroblast growth factor receptor (FGFR) testing across the bladder cancer care continuum: From molecular classification to treatment selection
Klinische Entscheidungsschwellen für urinbasierte FGFR-Tests entlang des Blasenkarzinom-Versorgungspfads: von molekularer Klassifikation bis zur Therapiewahl
UroPrecision · 11.11.2026
DOI: 10.1002/uro2.70093 ↗Auf einen Blick
Das Modell untersuchte, welchen Nutzen urinbasierte FGFR-Tests bei uninformativem Gewebetest und in der Nachsorge haben könnten. Unter den modellierten Annahmen stieg die molekulare Klassifikationsabdeckung von 66,0 % auf 85,7 %.
Fragestellung
Welche Entscheidungsschwellen ergeben sich für urinbasierte FGFR-Tests im Blasenkarzinom-Versorgungspfad?
Methode
Deterministisches Schwellen- und Szenariomodell mit 1000 Patient:innen; Reflex-Urintestung nach uninformativem Gewebetest, Therapiewahl und 1-jährige Surveillance-Analogie.
Ergebnisse
Unter transportierten TAR-210-Annahmen stieg die Klassifikationsabdeckung von 66,0 % auf 85,7 %; 197,2 informative Ergebnisse und 82,8 FGFR-positive Ergebnisse pro 1000 Patient:innen. Bei 80 % Akzeptanz und 80 % Therapieumsetzung wurden 51,4 zusätzliche true-positive Patient:innen behandelt; erforderlich waren 0,193 QALY pro behandelter Person.
Einschränkungen
Das Modell schätzt keine vergleichende Wirksamkeit oder inkrementelle Kosten-Effektivität. Mehrere Annahmen wurden aus anderen Datenquellen übernommen.
Schlussfolgerung der Autor:innen
Das Modell zeigt zwei bedingte Nutzenmechanismen urinbasierter FGFR-Tests: Gewinn verwertbarer FGFR-Klassifikation bei uninformativem Gewebetest und eine hypothetische Reduktion invasiver Surveillance-Kontrollen.
Kernaussagen
- Klassifikationsabdeckung: 66,0 % auf 85,7 %
- 51,4 zusätzliche behandelte true-positive Patient:innen bei 80 % Akzeptanz/Uptake
- Surveillance-Analogie: Zystoskopien von 3,000 auf 1,364 pro Patient-Jahr
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift UroPrecision, online erschienen am 11.11.2026. Verfasst von William Jia und 2 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Fibroblast growth factor receptor (FGFR) alterations are clinically actionable in urothelial cancer, yet tissue‐based molecular testing may fail when specimens are unavailable, depleted, aged, low in tumor content, or analytically inadequate. Urine molecular testing has the potential to add value throughout the patient journey by identifying FGFR alterations when tissue testing is unsuccessful; however, published urine‐testing evidence comes from different assays, populations, and clinical settings, and therefore cannot establish the expected performance or clinical utility of a single integrated FGFR urine pathway.
Methods
A deterministic threshold‐and‐scenario model followed 1000 patients from tissue FGFR testing through reflex urine testing after an uninformative tissue result, treatment selection, and a 1‐year surveillance analogue. ANNAR tissue validity and positivity, and TAR‐210 urine yield and positivity, informed the reflex testing scenario as transported inputs; GALEAS Bladder sensitivity and specificity informed a separately labeled external cross‐assay calibration that does not validate the intended assay. A one‐time $2919.60 Current Procedural Terminology coding‐scale price proxy was applied after tissue failure. The model calculated the minimum discounted quality‐adjusted life‐year (QALY) gain required per additionally treated true‐positive patient at $100 000/QALY; it did not estimate comparative effectiveness or an incremental cost‐effectiveness ratio. The surveillance stage hypothetically compared three annual cystoscopy‐based encounters with one retained safety cystoscopy and two urine‐monitoring intervals, using an 18.2% confirmatory‐cystoscopy trigger rate borrowed from a non‐FGFR marker trial and a provisional $597.91 price proxy per interval. The primary perspective was the US payer; patient and limited societal consequences were reported separately.
Results
Under transported TAR‐210 inputs, reflex urine FGFR testing increased scenario‐projected molecular‐classification coverage from 66.0% to 85.7%, adding 197.2 informative results and 82.8 projected FGFR‐positive results per 1000 patients. A separate GALEAS‐based cross‐study calibration estimated 80.3 true‐positive classifications; this was not an observed clinical yield for the intended assay. With 80% clinical acceptance and 80% treatment uptake, 51.4 additional cross‐study‐estimated true‐positive patients would be treated, and the required gain was 0.193 QALY, approximately 70 quality‐adjusted life‐days, per treated patient; full acceptance and uptake yielded an optimistic lower‐bound threshold of 0.124 QALY. In the hypothetical surveillance analogue, the borrowed 18.2% trigger reduced cystoscopies from 3.000 to 1.364 per patient‐year, avoiding 1.636 (54.5%). Payer break‐even required a complete displaced encounter cost of $730.94 before implementation costs; this exceeded the $281.24 office cystoscopy‐plus‐cytology estimate, so the analogue remained an incremental payer investment in that setting.
Conclusion
The model illustrates two conditional value mechanisms for FGFR‐focused urine testing: recovery of actionable FGFR classification when tissue testing is uninformative and a separate hypothetical reduction of selected invasive surveillance encounters. Economic favorability is conditional on intended‐assay performance, clinical acceptance, treatment uptake, complete episode costs, implementation costs, and retained oncologic safety.
Zitieren
APA
Jia, W., Nguyen, L., & Cheng, L. (2026). Clinical decision thresholds for urine‐based fibroblast growth factor receptor (FGFR) testing across the bladder cancer care continuum: From molecular classification to treatment selection. UroPrecision. https://doi.org/10.1002/uro2.70093
Vancouver
Jia W, Nguyen L, Cheng L. Clinical decision thresholds for urine‐based fibroblast growth factor receptor (FGFR) testing across the bladder cancer care continuum: From molecular classification to treatment selection. UroPrecision. 2026. doi:10.1002/uro2.70093
BibTeX
@article{Jia2026,
author = {Jia, William and Nguyen, Luciann and Cheng, Liang},
title = {Clinical decision thresholds for urine‐based fibroblast growth factor receptor (FGFR) testing across the bladder cancer care continuum: From molecular classification to treatment selection},
journal = {UroPrecision},
year = {2026},
doi = {10.1002/uro2.70093}
}
EUVIMED